Nanobiotix Transfers Phase 3 Head and Neck Cancer Trial Control to Johnson & Johnson
Nanobiotix SA has announced updates to the clinical development program for JNJ-1900 (NBTXR3), following the transfer of sponsorship and operational control of the ongoing Phase 3 NANORAY-312 head and neck cancer trial to Johnson & Johnson. The company reports that the transfer, initiated in the third quarter of 2024, is now complete in most regions. Nanobiotix estimates that interim data from the NANORAY-312 trial will be analyzed and reported in the first half of 2027, after the required number of events have occurred and the final patient has been recruited. Future updates related to this and other JNJ-1900 (NBTXR3) studies sponsored by Johnson & Johnson will be provided by J&J. No results have been presented at this time.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nanobiotix SA published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9551456-en) on October 24, 2025, and is solely responsible for the information contained therein.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。